See more : PT Maha Properti Indonesia Tbk (MPRO.JK) Income Statement Analysis – Financial Results
Complete financial analysis of Cyclo Therapeutics, Inc. (CYTH) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cyclo Therapeutics, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Mammoth Energy Services, Inc. (TUSK) Income Statement Analysis – Financial Results
- Orcadian Energy Plc (ORCA.L) Income Statement Analysis – Financial Results
- Turners Automotive Group Limited (TRA.AX) Income Statement Analysis – Financial Results
- Capital A Berhad (AIABF) Income Statement Analysis – Financial Results
- S. M. Gold Limited (SMGOLD.BO) Income Statement Analysis – Financial Results
Cyclo Therapeutics, Inc. (CYTH)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.cyclotherapeutics.com
About Cyclo Therapeutics, Inc.
Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease. The company also develops Trappsol Cyclo for the treatment of Alzheimer's disease. In addition, it sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is based in Gainesville, Florida.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.08M | 1.38M | 1.59M | 903.38K | 1.01M | 1.01M | 1.24M | 1.50M | 950.46K | 1.57M | 1.69M | 1.04M | 1.03M | 802.37K | 623.87K | 494.94K | 751.18K | 542.31K | 454.36K | 464.69K | 394.53K | 522.37K | 289.43K | 384.59K |
| Cost of Revenue | 98.46K | 138.93K | 156.08K | 66.40K | 75.49K | 105.03K | 132.92K | 198.43K | 124.43K | 272.64K | 426.02K | 139.68K | 273.76K | 114.66K | 110.83K | 99.32K | 118.40K | 125.19K | 66.66K | 78.83K | 45.43K | 84.48K | 34.03K | 99.22K |
| Gross Profit | 977.95K | 1.24M | 1.43M | 836.98K | 931.71K | 906.45K | 1.10M | 1.30M | 826.03K | 1.29M | 1.27M | 905.27K | 758.09K | 687.71K | 513.04K | 395.62K | 632.77K | 417.13K | 387.70K | 385.87K | 349.10K | 437.89K | 255.40K | 285.37K |
| Gross Profit Ratio | 90.85% | 89.90% | 90.16% | 92.65% | 92.50% | 89.62% | 89.26% | 86.80% | 86.91% | 82.61% | 74.84% | 86.63% | 73.47% | 85.71% | 82.24% | 79.93% | 84.24% | 76.92% | 85.33% | 83.04% | 88.48% | 83.83% | 88.24% | 74.20% |
| Research & Development | 14.18M | 9.00M | 9.15M | 6.10M | 4.87M | 2.71M | 2.29M | 1.86M | 658.51K | 94.13K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 5.66M | 7.81M | 6.50M | 3.68M | 3.43M | 2.43M | 2.62M | 2.64M | 2.22M | 1.53M | 639.54K | 560.17K | 799.60K | 678.64K | 693.33K | 520.06K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 3.90K | 13.06K | 18.34K | 5.01K | 5.89K | 5.64K | 7.85K | 7.16K | 7.57K | 10.90K | 8.91K | 10.81K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 6.83M | 7.82M | 6.52M | 3.68M | 3.44M | 2.44M | 2.63M | 2.65M | 2.23M | 1.55M | 648.45K | 570.98K | 799.60K | 678.64K | 693.33K | 520.06K | 439.10K | 350.68K | 500.32K | 664.78K | 263.50K | 240.54K | 279.11K | 548.79K |
| Other Expenses | 0.00 | 30.50K | 27.54K | 19.95K | 13.98K | 13.95K | 19.77K | 130.95K | 202.02K | 217.52K | 188.76K | 159.93K | 32.75K | 20.94K | 20.65K | 22.87K | 439.10K | 350.68K | 500.32K | 664.78K | 263.50K | 240.54K | 279.11K | 575.21K |
| Operating Expenses | 21.04M | 16.85M | 15.70M | 9.80M | 8.32M | 5.16M | 4.95M | 4.65M | 3.09M | 1.86M | 837.21K | 730.91K | 832.35K | 699.58K | 713.98K | 542.93K | 439.10K | 350.68K | 500.32K | 664.78K | 263.50K | 240.54K | 279.11K | 575.21K |
| Cost & Expenses | 21.13M | 16.99M | 15.85M | 9.86M | 8.40M | 5.27M | 5.08M | 4.85M | 3.22M | 2.13M | 1.26M | 870.59K | 1.11M | 814.24K | 824.81K | 642.25K | 557.51K | 475.86K | 566.97K | 743.61K | 308.93K | 325.02K | 313.14K | 674.43K |
| Interest Income | 0.00 | 12.47K | 3.41K | 19.80K | 12.03K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.51K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 28.60K | 31.29K | 33.67K | 53.87K | 61.80K | 25.81K | 4.31K | 0.00 | 1.82K | 10.75K | 11.05K | 13.96K | 12.03K | 22.60K | 30.92K | 35.44K | 28.29K | |
| Depreciation & Amortization | 19.28K | 19.48K | 16.83K | 12.76K | 5.68K | 10.12K | 9.27K | 107.10K | 169.03K | 152.45K | 148.04K | 142.64K | 32.75K | 20.94K | 20.58K | 22.87K | 24.37K | 27.46K | 35.01K | 27.76K | 37.82K | 24.19K | 51.29K | 26.41K |
| EBITDA | -20.03M | -15.60M | -14.27M | -8.95M | -7.39M | -4.24M | -3.82M | -4.09M | -2.23M | -406.57K | 486.82K | 303.65K | -39.21K | 12.72K | -172.55K | -188.55K | 218.04K | -63.32K | -77.60K | -251.15K | 90.92K | 221.54K | 27.58K | -66.02K |
| EBITDA Ratio | -1,860.90% | -1,145.03% | -897.54% | -992.49% | -719.16% | -419.60% | -309.54% | -215.26% | -220.57% | -26.15% | 34.14% | 30.34% | -4.02% | 1.13% | -28.91% | -25.14% | 26.28% | 46.31% | -56.50% | 4.17% | 29.51% | 42.57% | 8.63% | -69.09% |
| Operating Income | -20.05M | -15.61M | -14.27M | -8.96M | -7.39M | -4.27M | -3.84M | -4.21M | -2.41M | -562.31K | 336.65K | 157.49K | -74.26K | -11.87K | -200.94K | -239.47K | 193.67K | -45.90K | -112.61K | -278.91K | 85.60K | 197.35K | -23.71K | -289.84K |
| Operating Income Ratio | -1,862.69% | -1,134.76% | -899.77% | -991.85% | -733.80% | -421.84% | -310.51% | -279.85% | -253.22% | -35.87% | 19.88% | 15.07% | -7.20% | -1.48% | -32.21% | -48.38% | 25.78% | -8.46% | -24.78% | -60.02% | 21.70% | 37.78% | -8.19% | -75.36% |
| Total Other Income/Expenses | -7.25K | 171.00K | 3.41K | 19.80K | 12.03K | 11.77K | 10.26K | -17.95K | -24.62K | -30.37K | -51.74K | -58.29K | -23.51K | -662.00 | 7.81K | 26.24K | 9.89K | -168.28K | 165.15K | -282.58K | -15.63K | -31.77K | -32.83K | 171.41K |
| Income Before Tax | -20.06M | -15.45M | -14.29M | -8.94M | -7.53M | -4.26M | -3.83M | -4.22M | -2.43M | -592.69K | 284.91K | 99.20K | -97.77K | -12.53K | -193.13K | -213.23K | 203.55K | -101.83K | 52.54K | -561.49K | 69.98K | 165.58K | -56.54K | -315.83K |
| Income Before Tax Ratio | -1,863.36% | -1,123.08% | -900.94% | -989.80% | -747.87% | -420.68% | -309.68% | -281.04% | -255.81% | -37.81% | 16.83% | 9.49% | -9.47% | -1.56% | -30.96% | -43.08% | 27.10% | -18.78% | 11.56% | -120.83% | 17.74% | 31.70% | -19.54% | -82.12% |
| Income Tax Expense | 0.00 | -171.00K | 18.52K | -18.53K | 141.75K | 11.77K | 0.00 | 28.60K | 120.00K | 33.67K | 80.00K | 25.00K | 25.81K | 25.00K | 0.00 | 200.00K | -450.00K | 168.28K | 225.00K | 282.58K | -225.00K | 31.77K | 90.17K | 195.00K |
| Net Income | -20.06M | -15.28M | -14.31M | -8.92M | -7.67M | -4.26M | -3.83M | -4.22M | -2.55M | -592.69K | 204.91K | 74.20K | -97.77K | -37.53K | -193.13K | -413.23K | 653.55K | -101.83K | -172.46K | -561.49K | 294.98K | 165.58K | -113.88K | -510.83K |
| Net Income Ratio | -1,863.36% | -1,110.65% | -902.10% | -987.75% | -761.94% | -420.68% | -309.68% | -281.04% | -268.44% | -37.81% | 12.10% | 7.10% | -9.47% | -4.68% | -30.96% | -83.49% | 87.00% | -18.78% | -37.96% | -120.83% | 74.77% | 31.70% | -39.35% | -132.82% |
| EPS | -1.23 | -1.81 | -2.25 | -5.58 | -7.09 | -5.20 | -5.32 | -6.67 | -4.54 | -1.17 | 1.00 | 1.00 | -0.27 | -0.11 | -0.67 | -1.76 | 3.60 | -0.69 | -1.44 | -7.76 | 5.00 | 3.00 | -2.59 | -13.80 |
| EPS Diluted | -1.23 | -1.81 | -2.25 | -5.58 | -7.09 | -5.20 | -5.32 | -6.67 | -4.54 | -1.17 | 1.00 | 1.00 | -0.27 | -0.11 | -0.67 | -1.76 | 3.60 | -0.69 | -1.44 | -7.76 | 5.00 | 3.00 | -2.59 | -13.80 |
| Weighted Avg Shares Out | 16.33M | 8.44M | 6.37M | 1.60M | 1.08M | 817.57K | 720.37K | 633.54K | 562.09K | 505.43K | 371.66K | 366.80K | 358.07K | 337.11K | 287.51K | 235.33K | 179.20K | 148.15K | 120.18K | 72.32K | 50.05K | 47.91K | 43.89K | 37.02K |
| Weighted Avg Shares Out (Dil) | 16.33M | 8.44M | 6.37M | 1.60M | 1.08M | 817.57K | 720.37K | 633.54K | 562.09K | 505.43K | 371.66K | 366.80K | 358.07K | 337.11K | 287.51K | 235.33K | 179.20K | 148.15K | 120.18K | 72.32K | 50.05K | 47.91K | 43.89K | 37.02K |
7 Beaten Down Stocks with Significant Insider Buying
Insider buying could be a bullish sign for a stock. Insiders may sell their shares for many reasons.
CYTH Stock Price Increases Over 10% Pre-Market: Why It Happened
The stock price of Cyclo Therapeutics Inc (NASDAQ: CYTH) has increased by over 10% pre-market. This is why it happened.
Cyclo Therapeutics Meets Primary Efficacy Endpoint in Phase 1/2 Trial from Intravenous Trappsol® Cyclo™ in Rare Disease Niemann-Pick Type C1 (NPC1)
GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families suffering from diseases, today announced topline data from its Phase...
Cyclo Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results
GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families suffering from diseases, today reported its financial results for the...
Cyclo Therapeutics to Participate in Inaugural Emerging Growth Virtual Conference
GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families suffering from disease, today announced that N. Scott Fine, CEO...
Cyclo Therapeutics Appoints Russ Belden as Acting Chief Commercial Officer
GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families suffering from disease, today announced the appointment of Russ Belden...
Cyclo Therapeutics Announces Last Patient Last Visit in Phase 1/2 Trial Evaluating Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C
GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families suffering from disease, today announced that the last patient completed...
Cyclo Therapeutics Presents Positive Data from Clinical Development Program for Lead Candidate, Trappsol® Cyclo™, at WORLDSymposium 2021
GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company developing cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C and Alzheimer's disease, today announced the presentation of favorable data from its...
7 Stocks With Insider Buying
Insider buying could be a bullish signal for a stock. Why? The insiders may sell for a number of reasons.
Why Cyclo, Vivos Therapeutics And More Are Moving Today
Cyclo Therapeutics (NASDAQ: CYTH) shares are trading higher Tuesday after the company announced "positive" efficacy data from an extension protocol with Trappsol Cyclo in patients with Niemann-Pick Disease Type C. Cyclo Therapeutics is a U.S.-based biotechnology firm engaged in the marketing and...
Source: https://incomestatements.info
Category: Stock Reports